07.01.07
A recent study published in Alternative Medicine Review magazine (vol. 12, Number 1, 2007) presents further evidence of the superior cancer-inhibiting activity of Maitake Products’ Grifron-Pro Maitake D-Fraction (GD) on human bladder cancer cells over other natural anti-cancer products.
Dr. Sensuke Konno of New York Medical College conducted studies on GD and seven other commercially available products against human bladder cancer cells (T24). Such products compared in the study consisted of other mushrooms, mushroom extracts, beta-glucan based on an extract of yeast and an arabinoxylan product based on rice bran and Shiitake mushroom.
As a result, GD showed >90% cell growth reduction at the concentration of 240Ìg/mL—GD presented even greater effect when combined with vitamin C, reconfirming the fact that vitamin C would act synergistically with this fraction to potentiate its bioactivity.
Grifron-Pro Maitake D-Fraction is the very first mushroom supplement based on the standardized extract that has received IND approval for clinical studies on breast and prostate cancers by the FDA.
For further information: 973-470-0010.
Dr. Sensuke Konno of New York Medical College conducted studies on GD and seven other commercially available products against human bladder cancer cells (T24). Such products compared in the study consisted of other mushrooms, mushroom extracts, beta-glucan based on an extract of yeast and an arabinoxylan product based on rice bran and Shiitake mushroom.
As a result, GD showed >90% cell growth reduction at the concentration of 240Ìg/mL—GD presented even greater effect when combined with vitamin C, reconfirming the fact that vitamin C would act synergistically with this fraction to potentiate its bioactivity.
Grifron-Pro Maitake D-Fraction is the very first mushroom supplement based on the standardized extract that has received IND approval for clinical studies on breast and prostate cancers by the FDA.
For further information: 973-470-0010.